497 related articles for article (PubMed ID: 31200820)
1. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
2. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
[TBL] [Abstract][Full Text] [Related]
3. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
4. Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
Haque W; Verma V; Butler EB; Teh BS
Lung Cancer; 2019 Apr; 130():93-100. PubMed ID: 30885358
[TBL] [Abstract][Full Text] [Related]
5. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study on the effects of neoadjuvant chemotherapy on lymph node ratio, prognosis, and survival analysis of stage ⅢA-N2 non-small cell lung cancer].
Wei YL; Cui YH; Dong YH; Shi WJ
Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(4):259-264. PubMed ID: 33486934
[No Abstract] [Full Text] [Related]
7. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase.
Liu J; Hancock JG; Moreno AC; Wang Z; Boffa DJ; Detterbeck FC; Kim AW
Eur J Cardiothorac Surg; 2016 Feb; 49(2):596-601. PubMed ID: 25890936
[TBL] [Abstract][Full Text] [Related]
9. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
Urban D; Bar J; Solomon B; Ball D
J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
[TBL] [Abstract][Full Text] [Related]
10. Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.
Tamura M; Matsumoto I; Saito D; Yoshida S; Takata M; Takemura H
World J Surg Oncol; 2016 Nov; 14(1):295. PubMed ID: 27884195
[TBL] [Abstract][Full Text] [Related]
11. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
[TBL] [Abstract][Full Text] [Related]
12. Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
Deng W; Xu T; Wang Y; Xu Y; Yang P; Gomez D; Liao Z
Lung Cancer; 2018 Aug; 122():60-66. PubMed ID: 30032846
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
15. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
16. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.
Lee H; Ahn YC; Pyo H; Kim B; Oh D; Nam H; Lee E; Sun JM; Ahn JS; Ahn MJ; Park K; Choi YS; Kim J; Zo JI; Shim YM
Ann Surg Oncol; 2014 Jun; 21(6):2083-90. PubMed ID: 24522994
[TBL] [Abstract][Full Text] [Related]
18. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
[TBL] [Abstract][Full Text] [Related]
20. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.
Taylor MD; LaPar DJ; Thomas CJ; Persinger M; Stelow EB; Kozower BD; Lau CL; Jones DR
Ann Thorac Surg; 2013 Oct; 96(4):1163-1170. PubMed ID: 23998409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
